Lorna joined the CSL Group in 2013. She was appointed to the role of VP, Pandemic Response Solutions for Seqirus late in 2019 and was previously VP, Commercial Operations Asia Pacific for Seqirus where she was instrumental in enhancing our presence across the Asia Pacific region. Lorna has enjoyed a successful career in the pharmaceutical industry, encompassing clinical research, business development, marketing and sales, across a wide variety of therapeutic areas, including Respiratory, Central Nervous System, Cardiopulmonary, Metabolic, Psychiatry, Neurology, HOV and Vaccines in Europe, US and Asia. She immigrated to Australia in 2002 and worked for GSK Australia as the Commercial Vice President for five years, driving company recognised best commercial practice in respiratory, sexual health and paediatric vaccines. From 2008 to 2012, as General Manager she successfully established Ikaria Australia Pty Ltd, a biotherapeutics company commercialising pharmaceutical products and devices for intensive care use. Lorna graduated with a PhD in Neurobiology (University College London); BSc in Pharmacology (University of Glasgow) and went on to hold academic positions at the Cardiothoracic Institute at the Royal Brompton Hospital (London) and at the Royal Post Graduate Medical School (London).
Vice President, Interim Commercial Head International Markets